Skip to main content
Fig. 2 | Cardio-Oncology

Fig. 2

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

Fig. 2

Change in ejection fraction points at surveillance months from baseline (pre-chemotherapy). In patients with who did not experience TIC (pEF), change in EF from baseline at 3-month surveillance intervals was not significantly different. In patients with developed TIC (rEF), a reduction in greater than 15 points from baseline was detected as early as 4 months with overall persistent depression at 15 months from baseline. The reduction in EF was significantly different than pEF at all time points (p < 0.05). EF: ejection fraction, pEF: patients who did not develop TIC/preserved EF, rEF: patients who developed TIC/reduced EF

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us